1. Scrip
  2. >>Advanced Therapies
  3. >>Gene Therapies

Positive Fabry Data Should Smooth Way For Sangamo’s Partnering Efforts

 
• By Alaric DeArment

The biotech announced results from the pivotal trial of isaralgagene civoparvovec and plans to file for approval in 2026 as it looks for a commercialization partner.

DNA
(Shutterstock)

Sangamo Therapeutics’ efforts to secure a partnership for ST-920 (isaralgagene civoparvovec), its gene therapy for Fabry disease, should get easier now that the biotech has positive pivotal data supporting a US Food and Drug Administration filing.

Key Takeaways
  • Sangamo unveiled positive data from the pivotal STAAR trial of ST-920 and plans to seek approval for the therapy in Fabry disease in 2026.  

The Richmond, Calif.-based, gene therapy-focused biotech said June 24 that the pivotal Phase I/II STAAR study met the endpoint –...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Gene Therapies

More from Business

Cogent Peaks With Bezaclastinib SUMMIT Results

 
• By Alaric DeArment

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By Kevin Grogan

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

In Brief: Concentra Snaps Up Struggling IGM Biosciences In Latest Biotech Deal

 
• By Sushmita Panda

Concentra Biosciences is acquiring struggling IGM Biosciences for $1.25 per share plus a contingent value right, with the deal expected to close in August 2025.